The heterogeneous nuclear ribonucleoprotein Q (hnRNPQ), also known as SYNCRIP, is a member of the hnRNP family involved in RNA metabolism, including mRNA processing, transport, stability, and translation regulation. It contains RNA-binding domains that enable interactions with diverse RNA targets, playing roles in alternative splicing, localization, and viral RNA replication. hnRNPQ antibodies are essential tools for studying its function in cellular processes and disease contexts. These antibodies are typically developed using immunogenic regions of the protein, such as its N-terminal or C-terminal domains, and are validated for specificity in applications like Western blotting, immunoprecipitation, and immunofluorescence. hnRNPQ dysregulation has been linked to neurological disorders (e.g., ALS, spinal muscular atrophy) and cancers, where it influences oncogene expression and metastasis. Researchers use hnRNPQ antibodies to investigate its interactions with RNA molecules, protein partners, and its subcellular distribution under stress or pathological conditions. Variations in isoforms (e.g., Q, R) due to alternative splicing require antibodies targeting unique epitopes to ensure isoform-specific detection. Its molecular weight (~70-80 kDa) aids in identifying proper bands in assays. Overall, hnRNPQ antibodies are pivotal in unraveling its contributions to gene regulation and disease mechanisms.